Risk-based prophylactic HPV vaccination of heterosexual US men aged 27 to 45 years for prevention of oropharyngeal cancer.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 41556877.
- Also identified by DOI 10.1093/infdis/jiag038.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
HPV vaccination of US individuals aged 27-45 years is recommended through shared clinical decision-making. To enable shared decision-making, we used a microsimulation-based state-transition model to develop and validate a risk-prediction model to identify heterosexual men aged 27-45 at high-risk of acquiring oral HPV16 infections. A risk model for incident oral HPV16 infections had good discrimination (AUC=0.73) and calibration (E/O=1.01) in internal cross-validation. Compared to vaccinating all men aged 27-45, vaccinating 44% of men with highest model-predicted risk would prevent 80% of incident oral HPV16 infections through age 45 and reduce the NNV to prevent 1 infection by 45% (184 vs. 100).